Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2840 - Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Cytology Proven Axillary Node-Positive Breast Cancer at Diagnosis

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Hee Jun Choi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

H.J. Choi1, S.M. Jung1, J.M. Ryu2, I. Kim1, S.J. Nam1, S.W. Kim2, J. Yu2, S.K. Lee2, J.E. Lee2

Author affiliations

  • 1 Breast Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 2 Department Of Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
More

Resources

Abstract 2840

Background

This study aimed to evaluate the prognostic effects of sentinel lymph node biopsy (SLNB) on recurrence and survival after neoadjuvant chemotherapy (NAC) in patients with cytology-proven axillary node metastasis breast cancer.

Methods

This study is a registered medical record review based on a prospectively collected cohort. We selected 506 patients who were diagnosed with invasive breast cancer and axillary lymph nodes metastasis and treated with NAC followed by curative surgery at Samsung Medical Center between January 2007 and December 2014. We classified patients into three groups: Group A, negative SLN status and no further dissection; Group B, negative SLN status with backup axillary lymph node dissection (ALND); and Group C, no residual axillary metastasis on pathology with ALND regardless of clinical response. We analyzed and compared outcomes including prognoses and survival among all groups.

Results

The median age at the time of surgery was 44.4 years. The median follow-up time was 47.0 months (range: 3-115 months) and the median number of retrieved SLNs was 5.0. The SLN identification rate was 98.3% (234/238 patients), and the false negative rate (FNR) of SLNB after NAC was 7.5% (8/106 patients). There was no significant difference in disease-free survival (DFS, p = 0.578) or overall survival (OS, p = 0.149) among Groups A, B, and C.

Conclusions

These results suggest that SLNB can be feasible and oncologically safe after NAC for node-positive breast cancer and could help reduce arm morbidity by avoiding standard ALND in negative SLN patients.

Clinical trial identification

Legal entity responsible for the study

Samsung Medical Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings